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Identification of coding variant associations for complex diseases offers a direct route to 
biological insight, but is dependent on appropriate inference concerning the causal impact 
of those variants on disease risk. We aggregated exome-array and exome sequencing data 
for 81,412 type 2 diabetes (T2D) cases and 370,832 controls of diverse ancestry, 
identifying 40 distinct coding variant association signals (at 38 loci) reaching significance 
(p<2.2x10-7). Of these, 16 represent novel associations mapping outside known genome-
wide association study (GWAS) signals. We make two important observations. First, 
despite a threefold increase in sample size over previous efforts, only five of the 40 signals 
are driven by variants with minor allele frequency <5%, and we find no evidence for low-
frequency variants with allelic odds ratio >1.36. Second, we used GWAS data from 50,160 
T2D cases and 465,272 controls to fine-map associated coding variants in their regional 
context, with and without additional weighting, to account for the global enrichment of 
complex trait association signals in coding exons. We demonstrate convincing support 
(posterior probability >80% under the “annotation-weighted” model) that coding variants 
are causal for the association at 16 of the 40 signals (including novel signals involving 
POC5 p.His36Arg, ANKH p.Arg187Gln, WSCD2 p.Thr113Ile, PLCB3 p.Ser778Leu, and 
PNPLA3 p.Ile148Met). However, one third of coding variant association signals represent 
“false leads” at which naïve analysis would have led to an erroneous inference regarding 
the effector transcript mediating the signal. Accurate identification of validated targets is 
dependent on correct specification of the contribution of coding and non-coding mediated 
mechanisms at associated loci. 
 
Genome-wide association studies (GWAS) have identified many thousands of 
association signals influencing common, complex traits such as type 2 diabetes (T2D) and 
obesity1-7. Most of these significant association signals involve common variants that map to 
non-coding sequence and identification of their cognate effector transcripts has often 
proved challenging. The identification of coding variants causally implicated in trait 
predisposition offers a more direct route from association signal to biological inference.  
The exome occupies only 1.5% of overall genome sequence, but modelling of complex 
trait architecture indicates that, for many common diseases, coding variants make a 
disproportionately large contribution to trait heritability8,9. This enrichment indicates that 
coding variant association signals have an enhanced probability of being causal when 
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compared to those involving an otherwise equivalent non-coding variant. This does not, 
however, guarantee that all coding variant associations are causal. Alleles driving common-
variant (minor allele frequency [MAF] ≥5%) GWAS signals typically reside on extended risk 
haplotypes that, due to linkage disequilibrium (LD), incorporate many common variants10,11. 
Consequently, the presence of a coding allele on the risk haplotype does not constitute 
sufficient evidence that it represents the causal variant at the locus, or that the gene within 
which it lies is mediating the association signal. Since much coding variant discovery has 
proceeded through exome-specific analyses via exome-array genotyping or exome 
sequencing, researchers have often been poorly-placed to position coding variant 
associations in the context of regional genetic variation, and it is unclear how often this may 
lead to incorrect assumptions regarding their causal role.  
In our recent study of T2D predisposition12, we surveyed the exomes of 34,809 T2D 
cases and 57,985 controls, of predominantly (>90%) European descent, and identified 13 
distinct coding variant associations reaching genome-wide significance. Twelve of these 
associations involved common variants, but the data hinted at a substantial pool of near-
significant lower-frequency coding variants of moderate impact (allelic odds ratio [OR] 
between 1.5 and 3.0) that might be amenable to detection in larger samples. We also 
reported that, whilst many of these signals fell within common variant loci previously 
identified by GWAS, it was often far from trivial to determine, using available data, whether 
those coding variants were causal or simply ‘hitchhiking’ on risk haplotypes.  
Here, we report analyses that address these two key issues. First, we extended the 
scope of our exome-array genotyping study to include data from 81,412 T2D cases and 
370,832 controls of diverse ancestry, substantially expanding our power to detect coding 
variant associations across the allele-frequency spectrum. Second, we undertook high-
resolution fine-mapping of the detected signals in 50,160 T2D cases and 465,272 controls 
with genome-wide genotyping data, to understand the extent to which the identification of 
coding variant associations provides a reliable guide to causal mechanisms. 
 
RESULTS 
 
Study overview. We aggregated T2D association summary statistics from 54 studies in up to 
452,244 individuals (effective sample size 228,825) across five ancestry groups 
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(Supplementary Tables 1 and 2): African American, East Asian, European, Hispanic/Latino, 
and South Asian. These included: (a) 58,425 cases and 188,032 controls genotyped with the 
exome array; (b) 14,608 cases and 174,322 controls from UK Biobank and GERA (Resource 
for Genetic Epidemiology on Adult Health and Aging) genotyped with GWAS arrays enriched 
for exome content and/or coverage of low-frequency variation across ethnic groups13,14; and 
(c) 8,379 cases and 8,478 controls with whole-exome sequence from the GoT2D/T2D-
GENES12 and SIGMA15 studies. Overall, this represented a 3-fold increase in effective sample 
size over our previous study of T2D predisposition12. We performed European-specific (EUR, 
60.9% of total effective sample size) and trans-ethnic (TE) meta-analyses of variants 
delineated by exome-array content (247,470 variants), with and without adjustment for 
body mass index (adjBMI).  
We considered p<2.2x10-7 as significant for protein truncating variants (PTVs) and 
moderate impact coding variants (including missense, in-frame indel and splice region 
variants) based on a weighted Bonferroni correction that accounts for the observed 
enrichment in complex trait association signals mapping to coding variation16. This threshold 
is close to that obtained through other approaches such as simple Bonferroni correction for 
the total number of coding variants on the array (Methods). Compared to our previous 
study12, the expanded sample size substantially increased power to detect association for 
common variants of modest effect (e.g. from 14.4% to 97.9% for a variant with 20% MAF 
and OR=1.05) and lower-frequency variants with larger effects (e.g. from 11.8% to 97.5% for 
a variant with 1% MAF and OR=1.20) assuming homogenous allelic effects across ancestry 
groups (Methods).  
 
Insights into coding variant association signals underlying T2D susceptibility. We detected 
significant associations at 69 coding variants under an additive genetic model, mapping to 
38 loci (Supplementary Fig. 1, Supplementary Table 3). Of these, 52 (at 29 loci) were 
significant in the European-specific analysis, and 62 (at 35 loci) in the trans-ethnic analysis. 
Variants at PLCB3, C17orf58, and ZHX3 were only significant in the European-specific 
analysis. We observed minimal evidence of heterogeneity in allelic OR between ancestry 
groups (Supplementary Table 3), and no compelling evidence for non-additive allelic 
effects, irrespective of allele frequency (Supplementary Fig. 2, Supplementary Table 4). 
Reciprocal conditional analyses (Methods) indicated that the 69 coding variants represented 
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40 distinct association signals (conditional p<2.2x10-7) across the 38 loci, with two distinct 
signals each at HNF1A and RREB1 (Supplementary Table 5). These 40 signals included the 13 
associations reported in our earlier publication12, all of which demonstrated more significant 
associations in this expanded trans-ethnic meta-analysis (Supplementary Table 6). 
 Sixteen of the 40 distinct association signals mapped outside regions previously 
implicated in T2D susceptibility, defined as >500kb from the reported lead GWAS SNPs 
(Table 1). These included signals involving missense variants in POC5 (p.His36Arg, 
rs2307111, pTE=1.6x10-15), PNPLA3 (p.Ile148Met, rs738409, pTEadjBMI=2.8x10-11), and ZZEF1 
(p.Ile2014Val, rs781831, pTE=8.3x10-11).  
 
Contribution of low-frequency and rare coding variation to T2D susceptibility. Despite 
increased power and good coverage of low-frequency variants on the exome array (>80% of 
coding variants with MAF >0.5% in European ancestry populations12), all but five of the 40 
distinct coding variant association signals were common, with modest effects (allelic OR 
1.02-1.36) (Supplementary Fig. 3, Supplementary Table 3). The five association signals 
attributable to lower-frequency variants were also of modest effect (allelic OR 1.09-1.29) 
(Supplementary Fig. 3). Two of these lower-frequency variant signals represented novel 
protective associations against T2D: FAM63A p.Tyr95Asn (rs140386498, MAF=1.2%, OR= 
0.82 [0.77-0.88], pEUR=5.8x10-8) and ANKH p.Arg187Gln (rs146886108, MAF=0.4%, OR=0.78 
[0.69-87], pEUR=2.0x10-7). Both of these variants were very rare or monomorphic in non-
European individuals analysed in this study. 
 In Fuchsberger et al.12, we observed a pool of 100 low-frequency coding variants 
with modest effects (estimated allelic ORs between 1.10 and 2.66) for which the association 
evidence was strong but not genome-wide significant. In this expanded analysis, only five of 
these variants, including the two novel associations at FAM63A p.Tyr95Asn and ANKH 
p.Arg187Gln, achieved significance. More precise effect size estimation with the larger 
sample size indicates that the OR estimates in the earlier study were subject to a substantial 
upwards bias (Supplementary Fig. 3). 
To detect additional rare variant association signals, we performed gene-based 
analyses (burden and SKAT17) using previously-defined “strict” and “broad” masks, filtered 
for annotation and MAF18 (Methods). We identified gene-based associations with T2D 
susceptibility (p<2.5x10-6, Bonferroni correction for 20,000 genes) for FAM63A (SKAT broad 
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mask, 10 variants, combined MAF=1.90%, pEUR=3.1x10-9) and PAM (SKAT broad mask, 17 
variants, combined MAF=4.67%, pTE=8.2x10-9). On conditional analysis (Supplementary 
Table 7), we found that the gene-based signal at FAM63A was entirely accounted for by the 
low-frequency p.Tyr95Asn allele described earlier (SKAT broad mask, conditional p=0.26). In 
these data, the gene-based signal for PAM is also attributable to a single low-frequency 
variant (p.Asp563Gly; SKAT broad mask, conditional p=0.15). However, a second, previously-
described, low-frequency variant PAM p.Ser539Trp19 is not represented on the exome array, 
and thus did not contribute to our analyses. 
 
Fine-mapping of coding variant association signals with T2D susceptibility. The present 
study has identified 40 distinct coding variant associations with T2D, but this information is 
not sufficient to determine that the variants themselves are causal for the disease. To assess 
the role of these coding variants in the context of regional genetic variation at the locus, we 
fine-mapped the distinct association signals using a European ancestry GWAS meta-analysis 
including 50,160 T2D cases and 465,272 controls, aggregated from 24 studies by the 
DIAGRAM Consortium. Each component GWAS had been imputed using suitable high 
density reference panels (Methods, Supplementary Table 8): (i) 22 GWAS were imputed up 
to the Haplotype Reference Consortium20; (ii) the UK Biobank GWAS was imputed to a 
merged reference panel from the 1000 Genomes Project (multi-ethnic, phase 3, October 
2014 release)21 and the UK10K Project9; and (iii) the deCODE GWAS was imputed up to the 
deCODE Icelandic population-specific reference panel based on whole-genome sequence 
data19 (Methods, Supplementary Table 8). Distinct association signals were delineated 
before fine-mapping using approximate conditional analyses (Methods, Supplementary 
Table 5). We excluded the locus in the major histocompatibility complex because of the 
extended and complex structure of LD across the region, which complicates fine-mapping 
efforts.  
For each of the remaining 39 signals, we first constructed “functionally unweighted” 
credible variant sets which, at each locus, collectively account for 99% of the posterior 
probability (πU) of driving the association, based exclusively on the meta-analysis summary 
statistics22 (Methods, Supplementary Table 9). For each signal, we then calculated the total 
posterior probability attributed to coding variants (missense, in-frame indel, and splice 
region variants; Figure 1, Supplementary Fig. 4 and 5). Under this model, there were only 
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two signals at which coding variants accounted for ≥80% of the posterior probability of 
association: HNF4A p.Thr139Ile (rs1800961, πU>0.999) and RREB1 p. Asp1171Asn 
(rs9379084, πU=0.920). However, at other signals, including some, such as GCKR 
p.Pro446Leu and SLC30A8 p.Arg276Trp, where robust empirical evidence has established 
their causal role23,24, the genetic evidence supporting coding variant causation was weak. 
This is because coding variants were typically in high LD (r2>0.9) with large numbers of non-
coding variants, such that the posterior probabilities of association were distributed across 
many variants with broadly equivalent evidence for association.  
These functionally unweighted sets are based on genetic fine-mapping data alone, 
and do not account for the knowledge that coding variants are disproportionately 
represented amongst GWAS associations with complex traits8,9. To accommodate this 
knowledge, we extended these fine-mapping analyses by incorporating an “annotation 
informed” prior model of causality. We derived the priors from estimates of enrichment of 
association signals by sequence annotation from an analysis conducted by deCODE across 
96 quantitative and 123 binary phenotypes16 (Methods). This model “boosts” the priors and 
hence the posterior probability (πA) of coding variants. It also takes some account (in a 
tissue-non-specific way) of the GWAS enrichment of variants within enhancer elements (as 
assayed through DNase I hypersensitivity) as compared to non-coding variants mapping 
elsewhere. As expected, the annotation informed prior model generated smaller 99% 
credible sets across most signals, corresponding to fine-mapping at higher resolution 
(Supplementary Table 9). 
As expected, the estimated contribution of coding variants was increased under the 
annotation informed model. At one signal, the East Asian specific PAX4 p.Arg190His 
(rs2233580), the available fine-mapping data did not allow us to draw comprehensive 
conclusions on the contribution of coding variation to T2D susceptibility since the variant 
was not present in European GWAS. At the remaining 38 association signals, we could 
distinguish three broad patterns of causal relationships between coding variants and T2D 
risk. 
 
Group 1: T2D association signal is driven by coding variants. At 16 of the 38 distinct signals 
(after excluding those at MHC and PAX4), coding variation accounted for >80% of the 
posterior probability of the association signal under the annotation informed model (Figure 
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1, Table 2, Supplementary Table 9). This posterior probability was accounted for by a single 
coding variant at 12 signals and multiple coding variants at four. Reassuringly, group 1 
signals provided confirmation of coding variant causation for several loci at which functional 
studies (involving manipulation of the variant and/or effector gene) have reinforced genetic 
association data, establishing the role of GCKR, PAM, SLC30A8, and three variants in strong 
LD with each other at the KCNJ11-ABCC8 locus (Table 2). T2D association signals at the 12 
remaining signals (Fig. 1, Supplementary Table 9) had not previously been established to be 
driven by coding variation, but our fine-mapping analyses pointed to high probability causal 
coding variants after incorporating the annotation informed priors: these included HNF4A, 
RREB1 p. Asp1171Asn, ANKH, WSCD2, POC5, TM6SF2, HNF1A p.Ala146Val, GIPR, HNF1A 
p.Ile75Leu, LPL, PLCB3, and PNPLA3 (Table 2). At several of these loci, independent evidence 
corroborates the causal role of the genes harbouring the associated coding variants with 
respect to T2D-risk. For example, rare coding mutations at HNF1A and HNF4A are causal for 
monogenic, early-onset forms of diabetes25; and at TM6SF2 and PNPLA3, the coding variant 
concerned has been directly implicated in the development of non-alcoholic fatty liver 
disease (NAFLD)26,27. 
The use of priors capturing the enrichment of coding variants seems a reasonable 
model, genome-wide. However, at any given locus, strong priors (especially for PTVs) might 
elevate to apparent causality, variants, which, on the basis of genetic fine-mapping alone, 
would have been excluded from a causal role. However, comparison of the annotation 
informed and functionally unweighted credible sets, indicated that this was not the case for 
any of the 16 association signals in group 1. For 11 of the 16 (GCKR, PAM, KCNJ11-ABCC8, 
HNF4A, RREB1 p. Asp1171Asn, ANKH, POC5, TM6SF2, HNF1A p.Ala146Val, PLCB3, PNPLA3) 
the coding variant was the lead SNP in the fine-mapping analysis (Table 2), with the highest 
posterior probability of association, even under the functionally unweighted model. At 
SLC30A8, WSCD2, and GIPR, the coding variants had similar posterior probabilities of 
association as the lead non-coding SNPs under the functionally unweighted prior: SLC30A8 
p.Arg276Trp (rs13266634, πU=0.295) and (rs35859536, πU=0.388); WSCD2 p.Thr113Ile 
(rs3764002, πU=0.281) and rs1426371 (πU=0.475); and GIPR p.Glu138Gln (rs1800437, 
πU=0.169) and rs10423928 (πU=0.221). At these 14 signals therefore, the coding variants 
have either greater or equivalent posterior probabilities of association as the best flanking 
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non-coding SNPs under the functionally unweighted model, but receive a boost in the 
posterior probability after accounting for variant annotation. 
 The situation is less clear at the LPL locus. Here, fine-mapping resolution is poor 
under the functionally unweighted prior, and the coding variant resides on an extended 
haplotype in strong LD with non-coding variants, some with higher posterior probabilities, 
such as rs74855321 (πU=0.0481) (compared to LPL p.Ser474* [rs328, πU=0.0231]). However, 
because LPL p.Ser474* is annotated as a PTV, it benefits from a substantially increased prior 
that is reflected in the annotation informed ranking. Ultimately, a decision on the causal 
role of any such variant must rest on the amalgamation of evidence from diverse sources 
including detailed functional evaluation of the coding variants, and of other variants with 
which it is in LD. 
 At the HNF1A p.Ile75Leu signal, the total posterior probability attributed to coding 
variants under the annotation informed prior was 0.894. However, the total probability was 
accounted for by p.Gly226Ala (rs56348580, πA=0.894), a variant which is missing from the 
exome array. Conversely, the posterior probability attributed to the index coding variant, 
p.Ile75Leu (rs1169288) was <0.001, although this may reflect its absence from most 
commercial GWAS arrays and low-quality imputation. Fine-mapping analyses conducted 
using the Metabochip10, on which HNF1A p.Ile75Leu, as well as many local non-coding 
variants, are directly typed, demonstrates that these two coding variants are likely to be 
driving distinct association signals at this locus, and are consistent with our observations 
from the exome array. Direct genotyping or sequencing will be required to fully disentangle 
the relationships between the various coding variants at this signal. However, the 
established role of rare coding variants in HNF1A with respect to monogenic forms of 
diabetes leaves the role of HNF1A as a causal transcript at this locus in little doubt.  
 
Group2: T2D association signals are not attributable to coding variants. At 14 of the 38 
distinct signals, coding variation accounted for <20% of the posterior probability of driving 
the association, even after applying the annotation informed prior model that boosts coding 
variant posterior probabilities. These signals are likely to be driven by local non-coding 
variation and mediated through regulation of gene expression. Six of these signals (TPCN2, 
ZHX3, MLX, ZZEF1, C17orf58, and CEP68) represent novel T2D-association signals identified 
in the exome-focused analysis. On the basis of the exome-array discoveries, it would have 
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been natural to consider the named genes at these, and the other loci in this group, as 
strong candidates for mediation of their respective association signals. However, the fine-
mapping analyses suggest that these coding variant signals are irrelevant to biological 
inference. 
The coding variant association at the CENTD2 (ARAP1) locus is a case-in-point. The 
association with the p.Gln802Glu variant in ARAP1 (rs56200889, pTE=4.8x10-8 but πA<0.001 
in the annotation informed analysis) is clearly seen in the fine-mapping analysis to be 
secondary to a substantially stronger non-coding association signal involving a cluster of 
variants including rs11603334 (pTE=9.5x10-18, πA=0.0692) and rs1552224 (pTE=2.5x10-17, 
πA=0.0941). The identity of the effector transcript at this locus has been the subject of 
considerable investigation, and some early studies used islet expression data to highlight 
ARAP1 as the strongest candidate28. However, a more recent study integrating studies of 
human islet genomics and murine gene knockouts points firmly towards STARD10 as the 
gene mediating the GWAS signal, consistent with the reassignment of the ARAP1 coding 
variant association as irrelevant to biological inference at this locus29. 
 
Group 3: Fine-mapping data consistent with partial role for coding variants. At eight of the 
38 distinct signals, the total posterior probability attributable to coding variation in the 
annotation informed analyses was between 20% and 80%. At these signals, the evidence is 
consistent with “partial” contributions from coding variants, although the precise inference 
is likely to be locus-specific, dependent on subtle variations in LD, imputation accuracy, and 
the extent to which the global priors accurately represent the functional impact of the 
specific variants concerned.  
 This group includes PPARG at which independent evidence corroborates the causal 
role of this specific effector transcript with respect to T2D risk. PPARG encodes the target of 
antidiabetic thiazolidinedione drugs and is known to harbour rare coding variants that are 
causal for lipodystrophy and insulin resistance, both conditions highly relevant to T2D. The 
common variant association signal at this locus has generally been attributed to the 
p.Pro12Ala coding variant (rs1801282) although confirmation that this variant has an 
empirical impact on PPARG function has been difficult to obtain30-32. In the functionally 
unweighted analysis, p.Pro12Ala had an unimpressive posterior probability of being causal 
(πU=0.0238); after including annotation informed priors, the same variant emerged with the 
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highest posterior probability (πA=0.410), although the 99% credible set included 19 non-
coding variants, spanning 67kb (Supplementary Table 9). These credible set variants 
included rs4684847 (πA=0.00891), at which the T2D-associated allele has been reported to 
impact PPARG2 expression and insulin sensitivity by altering binding of the homeobox 
transcription factor PRRX133. These data are consistent with a model whereby regulatory 
variants contribute to the mechanisms through which the T2D GWAS signal impacts PPARG 
activity (in combination with or, potentially, to the exclusion of p.Pro12Ala). Future 
improvements in functional annotation for regulatory variants (gathered from relevant 
tissues and cell types) can be expected to provide increasingly granular priors that can be 
used to fine-tune assignment of causality at loci such as this.  
 
Functional impact of coding alleles. In other contexts, the functional impact of coding 
alleles is correlated with: (i) variant-specific features, including measures of conservation 
and predicted impact on protein structure; and (ii) gene-specific features such as extreme 
selective constraints as quantified by the intolerance to functional variation34. To determine 
whether similar measures could capture information pertinent to T2D causation, we 
compared coding variants falling into the different fine-mapping groups for a variety of 
measures including MAF, Combined Annotation Dependent Depletion score (CADD-score)35, 
and loss-of-function (LoF)-intolerance metric, pLI34 (Methods, Fig. 2). As noted previously35, 
CADD-score and MAF exhibit a negative correlation (Pearson’s correlation r=-0.44, 
p=0.0033) across association signals. Variants from group 1 had significantly higher CADD-
scores than those in group 2 (p=0.0017, by Kolmogorov-Smirnov test). With the exception of 
the variants at KCNJ11-ABCC8 and GCKR, all group 1 coding variants considered likely to be 
driving T2D association signals have CADD-score ≥20 (i.e. the 1% most deleterious variants 
predicted across the human genome). On this basis, we would predict that the coding 
variant at PAX4, for which the fine-mapping data were inconclusive, is also likely causal for 
T2D.  
 
Novel non-coding association signals for T2D susceptibility. Whilst the exome array 
primarily encompasses variation that alters protein function, it also incorporates previously 
reported non-coding lead SNPs from GWAS for a range of complex human phenotypes, 
including metabolic traits that may also impact T2D susceptibility. We detected novel 
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significant (p<5x10-8) associations with T2D status for 20 non-coding variants at 15 loci. 
Three of these (POC5, LPL, and BPTF) overlap with novel coding signals reported here 
(Supplementary Table 10). Lead SNPs at these loci had been included on the exome array as 
GWAS tags for association signals with metabolic traits including central and overall obesity, 
lipid levels, coronary heart disease, venous thromboembolism, and menarche, but here 
were demonstrated to be genome-wide significant for T2D as well (Supplementary Table 
10). If instead of the conventional genome-wide significance threshold, we adopted a 
weighted Bonferroni threshold for all non-coding variants of p<9.5x10-9, balancing the less 
stringent threshold, used for defining significance for coding variants, 10 of the 15 loci 
remained associated with T2D. 
 
T2D loci and physiological classification. The development of T2D involves dysfunction of 
multiple mechanisms. Systematic analyses of the physiological effects of known T2D risk 
variants have provided improved understanding of the key intermediate processes involved 
in the disease and the mechanisms through which many of those variants exert their 
primary impact on disease risk36. We obtained association summary statistics for a range of 
metabolic traits and other outcomes for 94 T2D-associated index variants representing the 
40 distinct coding signals and 54 distinct non-coding signals (including 12 novel and 42 
previously reported non-coding GWAS lead SNPs from the exome array). We applied 
hierarchical clustering techniques (Methods) to generate, multi-trait association patterns, 
and were able to allocate 71 of the 94 loci to one of three categories (Supplementary Fig. 6, 
Supplementary Table 11). The first category, comprising of nine T2D-risk loci with strong 
BMI and dyslipidemia phenotypes, included three of the novel coding signals: PNPLA3, 
which showed strong association with dyslipidemia, and POC5 and BPTF where the risk 
allele was associated with increased BMI (Supplementary Fig. 6, Supplementary Table 11). 
The T2D associations at both POC5 and BPTF were substantially attenuated (at least by 2-
fold decrease in -log10p) after adjusting for BMI (Table 1, Supplementary Table 3, 
Supplementary Fig. 7), indicating that the impact on T2D risk is likely mediated by a primary 
effect through increased adiposity. PNPLA3 and POC5 are established NAFLD26 and BMI6 
loci, respectively. The second category included 39 loci at which the multi-trait profiles 
indicated a primary effect on insulin secretion. This category included four of the novel 
coding variant signals (ANKH, ZZEF1, TTLL6, and ZHX3). The third category encompassed 23 
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loci with primary effects on insulin action including coding variant associations at KIF9, 
PLCB3, CEP68, TPCN2, FAM63A, and PIM3. For most variants in this category, the T2D-risk 
allele was associated with lower BMI, and T2D association signals were more pronounced 
after adjustment for BMI. At a subset of these loci, including KIF9 and PLCB3, T2D-risk alleles 
were associated with markedly larger waist-hip ratio and lower body fat percentage, 
indicating that their mechanism of action likely reflects limitations in storage capacity of 
peripheral adipose tissue37.  
 
DISCUSSION 
 
The present study adds to mounting evidence constraining the contribution of lower-
frequency variants to T2D risk. Although the exome array interrogates only a subset of the 
universe of coding variants, it does capture the majority (~80%) of low-frequency 
(MAF>0.5%) variants in European populations (and 48-75% in other major ancestral 
groups)12. The substantial increase in sample size in the present study provides more robust 
enumeration of the effect size distribution in this low-frequency variant range, and indicates 
that previous analyses are likely to have, if anything, overestimated the contribution of low-
frequency variants to T2D-risk.  
The present study is less informative regarding rare variants. These are sparsely 
captured on the exome array. In addition, the combination of greater regional diversity in 
rare allele distribution and the enormous sample sizes required to detect many rare variant 
associations (which would require meta-analysis of data from multiple diverse populations) 
acts against their detection. We note that our complementary genome and exome sequence 
analyses have thus far failed to register strong evidence for a substantial rare variant 
component to T2D-risk12.     
Once a coding variant association is detected, it is natural to assume a causal 
connection between that variant, the gene in which it sits, and the disease or phenotype of 
interest. Whilst such assignments may be robust for many protein-truncating alleles, we 
demonstrate that this implicit assumption is often inaccurate, particularly for associations 
attributable to common, missense variants. A third of the coding variant associations we 
detected were, when assessed in terms of regional LD, highly unlikely to be causal. At these 
loci, the genes within which they reside are consequently deprived of their implied 
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connection to disease risk, and attention redirected towards nearby non-coding variants 
and their impact on regional gene expression. As a group, coding variants we assign as 
causal are predicted to have a more deleterious impact on gene function than those that we 
exonerate, but, as in other settings, coding annotation methods lack both sensitivity and 
specificity. Besides, it is crucial to realise that empirical evidence that the associated coding 
allele is “functional” (i.e. that it can be shown to influence function of its cognate gene in 
some experimental assay) provides limited reassurance that the coding variant is 
responsible for the T2D association, unless that specific perturbation of gene function can 
itself be plausibly linked to the disease phenotype.  
Our fine-mapping analyses make use of the observation that coding variants are 
globally enriched across GWAS signals8,9,16 with greater prior probability of causality 
assigned to those with more severe impact on biological function. We assigned non-coding 
variants equivalently diminished priors, with lowest support for those mapping outside of 
DHS. The extent to which our findings corroborate previous assignments of causality (often 
backed up by detailed, disease appropriate functional assessment and orthogonal causal 
evidence) suggests that even these sparse annotations provide valuable information to 
guide target validation efforts. Nevertheless, we recognise that there are inevitable limits to 
the extrapolation of these broad-brush genome-wide enrichments to individual loci, and 
expect that improvements in functional annotation for both coding and regulatory variants, 
particularly when these are gathered from trait-relevant tissues and cell types, will provide 
more granular, trait-specific priors to fine-tune assignment of causality within associated 
regions. These will motivate target validation efforts that benefit from synthesis of both 
coding and regulatory routes to gene perturbation.    
The term “smoking gun” has often been used to describe the potential of functional 
coding variants to provide causal inference with respect to pathogenetic mechanisms38: our 
study provides a timely reminder that, even when a suspect with a smoking gun is found at 
the scene of a crime, it should not automatically be assumed that they fired the fatal bullet. 
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FIGURE LEGENDS 
 
Figure 1 | Posterior probabilities for coding variants across loci with annotation-informed 
priors. Fine-mapping of 38 distinct association signals was performed using European 
ancestry GWAS meta-analysis including 50,160 T2D cases and 465,272 controls. For each 
signal, we constructed a credible set of variants accounting for 99% of the posterior 
probability of driving the association, incorporating an “annotation informed” prior model 
of causality which “boosts” the posterior probability of driving the association signal that is 
attributed to coding variants. Each bar here represents a signal with the total probability 
attributed to the coding variants within the 99% credible set plotted on the y axis. When the 
probability (bar) is split across multiple coding variants (at least 0.05 probability attributed 
to a variant) at a particular locus, these are indicated by blue, pink, yellow, and green 
colours. The combined probability of the remaining coding variants are highlighted in grey. 
RREB1(a): RREB1 p. Asp1171Asn; RREB1(b): RREB1 p.Ser1499Tyr; HNF1A(a): HNF1A 
p.Ala146Val; HNF1A(b): HNF1A p.Ile75Leu; PPIP5K2 : PPIP5K2 p.Ser1207Gly; MTMR3: 
MTMR3 p.Asn960Ser; IL17REL: IL17REL p.Gly70Arg; NBEAL2: NBEAL2 p.Arg511Gly, KIF9: 
KIF9 p.Arg638Trp. 
 
Figure 2 | Plot of measures of variant-specific and gene-specific features of distinct coding 
signals to access the functional impact of coding alleles. Each point represents a coding 
variant with the minor allele frequency (MAF) plotted on the x axis and the Combined 
Annotation Dependent Depletion score (CADD-score) plotted on the y axis. Size of each 
point varies with the measure of intolerance of the gene to loss of function variants (pLI) 
and the colour represents the fine-mapping group each variant is assigned to. Group 1: 
Signal is driven by coding variant. Group 2: Signal attributable to non-coding variants. Group 
3: Consistent with partial role for coding variants. Unclassified category includes PAX4 and 
signal at TCF19 within the MHC region where we did not perform fine-mapping. The 
distribution of CADD-score between different groups is shown in the inset. 
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Table 1 | Index coding variants for T2D association signals (p<2.2x10-7) that map outside previously established susceptibility loci in trans-
ethnic meta-analysis of up to 81,412 cases and 370,832 controls. 
 
Locus Index variant Function rs ID Chr:Pos Alleles RAF BMI unadjusted BMI adjusted 
     Risk/Other  OR (95% CI) p-value OR (95% CI) p-value 
Trans-ethnic 
FAM63A FAM63A p.Tyr95Asn Missense rs140386498 1: 150,972,959 A/T 0.988 1.23 (1.15-1.32) 7.5x10-8 1.21 (1.14-1.29) 6.7x10-7 
CEP68 CEP68 p.Gly74Ser Missense rs7572857 2: 65,296,798 G/A 0.849 1.05 (1.03-1.07) 8.3x10-9 1.05 (1.03-1.07) 6.6x10-7 
KIF9 KIF9 p.Arg638Trp Missense rs2276853 3: 47,282,303 A/G 0.587 1.02 (1.01-1.04) 8.0x10-5 1.03 (1.02-1.04) 5.3x10-8 
ANKH ANKH p.Arg187Gln Missense rs146886108 5: 14,751,305 C/T 0.996 1.20 (1.06-1.36) 1.4x10-7 1.20 (1.07-1.34) 3.5x10-7 
POC5-ANKDD1B POC5 p.His36Arg Missense rs2307111 5: 75,003,678 T/C 0.551 1.04 (1.03-1.06) 1.6x10-15 1.02 (1.01-1.04) 2.1x10-5 
LPL LPL p.Ser474* Stop gain rs328 8: 19,819,724 C/G 0.905 1.05 (1.02-1.07) 6.8x10-9 1.05 (1.02-1.07) 2.3x10-7 
TPCN2 TPCN2 p.Val219Ile Missense rs72928978 11: 68,831,364 G/A 0.888 1.05 (1.03-1.08) 5.2x10-7 1.05 (1.03-1.07) 1.8x10-8 
WSCD2 WSCD2 p.Thr113Ile Missense rs3764002 12: 108,618,630 C/T 0.714 1.03 (1.01-1.04) 3.3x10-8 1.03 (1.01-1.04) 1.2x10-7 
ZZEF1 ZZEF1 p.Ile402Val Missense rs781831 17: 3,947,644 C/T 0.425 1.04 (1.03-1.06) 8.3x10-11 1.03 (1.02-1.05) 1.8x10-7 
MLX MLX p.Gln139Arg Missense rs665268 17: 40,722,029 G/A 0.301 1.03 (1.02-1.05) 2.0x10-8 1.03 (1.01-1.04) 1.1x10-5 
TTLL6 TTLL6 p.Glu712Asp Missense rs2032844 17: 46,847,364 C/A 0.760 1.03 (1.02-1.05) 1.2x10-7 1.03 (1.01-1.04) 0.00098 
PNPLA3 PNPLA3 p.Ile148Met Missense rs738409 22: 44,324,727 G/C 0.241 1.04 (1.03-1.06) 2.1x10-10 1.05 (1.03-1.06) 2.8x10-11 
PIM3 PIM3 p.Val300Ala Missense rs4077129 22: 50,356,693 T/C 0.283 1.04 (1.02-1.06) 1.9x10-7 1.04 (1.02-1.05) 3.5x10-8 
European-specific a 
PLCB3 PLCB3 p.Ser778Leu Missense rs35169799 11: 64,031,241 T/C 0.061 1.03 (1.00-1.06) 0.00012 1.05 (1.02-1.07) 1.7x10-6 
C17orf58-BPTF C17orf58 p.Ile92Val Missense rs9891146 17: 65,988,049 T/C 0.346 1.03 (1.02-1.05) 7.2x10-7 1.02 (1.00-1.03) 0.0027 
ZHX3 ZHX3 p.Asn310Ser Missense rs17265513 20: 39,832,628 C/T 0.172 1.04 (1.02-1.06) 6.8x10-6 1.03 (1.02-1.05) 3.2x10-5 
 
Chr: chromosome. Pos: Position build 37. RAF: risk allele frequency. BMI: body mass index. OR: odds ratio. CI: confidence interval. 
aAttained significance in European ancestry specific meta-analyses of up to 48,286 cases and 250,671 controls (Supplementary Table 3). 
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Table 2 | Posterior probabilities for coding variants within 99% credible set across loci 
with annotation informed and functionally unweighted prior. 
 
  
Chr: chromosome. Pos: Position build 37. πU: functionally unweighted prior; πA: annotation informed prior. Index coding 
variants are highlighted in bold. Fine-mapping analysis included 50,160 T2D cases and 465,272 controls.   
Locus Variant rs ID Chr Position 
Posterior probability 
Cumulative posterior probability attributed 
to coding variants 
πU πA πU πA 
MACF1 
MACF1 p.Ile39Val rs16826069 1 39,797,055 0.0121 0.240 
0.0317 0.628 MACF1 p.Met1424Val rs2296172 1 39,835,817 0.0113 0.224 
MACF1 p.Lys1625Asn rs41270807 1 39,801,815 0.00821 0.163 
FAM63A FAM63A p.Tyr95Asn rs140386498 1 150,972,959 0.00523 0.129 0.0122 0.303 
GCKR GCKR p. Pro 446Leu rs1260326 2 27,730,940 0.773 0.995 0.773 0.995 
THADA 
THADA p.Cys845Tyr rs35720761 2 43,519,977 <0.00100 0.0106 
0.00338 0.120 
THADA p.Thr897Ala rs7578597 2 43,732,823 0.00300 0.1070 
CEP68 CEP68 p.Gly74Ser rs7572857 2 65,296,798 <0.00100 0.00431 <0.00100 0.00431 
GRB14 COBLL1 p.Asn901Asp rs7607980 2 165,551,201 0.00583 0.160 0.00583 0.160 
PPARG PPARG p.Pro12Ala rs1801282 3 12,393,125 0.0238 0.410 0.0238 0.410 
KIF9 
SETD2 p.Pro1962Lys rs4082155 3 47,125,385 0.00812 0.171 
0.0183 0.384 NBEAL2 p.Arg511Gly rs11720139 3 47,036,756 0.00459 0.0967 
KIF9 p.Arg638Trp rs2276853 3 47,282,303 0.00278 0.0585 
IGF2BP2 SENP2 p.Thr291Lys rs6762208 3 185,331,165 <0.00100 <0.00100 <0.00100 <0.00100 
WFS1 WFS1 p.Val333Ile rs1801212 4 6,302,519 <0.00100 0.00129 <0.00100 0.00433 
ANKH ANKH p.Arg187Gln rs146886108 5 14,751,305 0.459 0.972 0.447 0.972 
POC5 POC5 p.His36Arg rs2307111 5 75,003,678 0.697 0.954 0.702 0.986 
PAM-PPIP5K2 
PAM p.Asp336Gly rs35658696 5 102,338,811 0.288 0.885 
0.309 0.947 
PPIP5K2 p.Ser1207Gly rs36046591 5 102,537,285 0.0204 0.0628 
RREB1 p.Asp1171Asn RREB1 p.Asp1171Asn rs9379084 6 7,231,843 0.920 0.997 0.920 0.997 
RREB1 p.Ser1499Tyr RREB1 p.Ser1499Tyr rs35742417 6 7,247,344 <0.00100 0.0128 0.00495 0.111 
LPL LPL p.Ser474* rs328 8 19,819,724 0.0231 0.832 0.0231 0.832 
SLC30A8 SLC30A8 p.Arg276Trp rs13266634 8 118,184,783 0.295 0.823 0.295 0.823 
GPSM1 GPSM1 p.Ser391Leu rs60980157 9 139,235,415 0.0310 0.557 0.0310 0.557 
KCNJ11-ABCC8 
KCNJ11 p.Val250Ile rs5215 11 17,408,630 0.208 0.412 
0.481 0.951 KCNJ11 p.Lys29Glu rs5219 11 17,409,572 0.190 0.376 
ABCC8 p.Ala1369Ser rs757110 11 17,418,477 0.0826 0.163 
PLCB3 PLCB3 p.Ser778Leu rs35169799 11 64,031,241 0.113 0.720 0.130 0.830 
TPCN2 TPCN2 p.Val219Ile rs72928978 11 68,831,364 <0.00100 0.00361 0.00601 0.140 
CENTD2 ARAP1 p.Gln802Glu rs56200889 11 72,408,055 <0.00100 <0.00100 <0.00100 <0.00100 
KLHDC5 MRPS35 p.Gly43Arg rs1127787 12 27,867,727 <0.00100 <0.00100 <0.00100 <0.00100 
WSCD2 WSCD2 p.Thr113Ile rs3764002 12 108,618,630 0.281 0.955 0.282 0.958 
HNF1A p.Ile75Leu 
HNF1A_Gly226Ala rs56348580 12 121,432,117 0.358 0.894 
0.358 0.894 
HNF1A p.Ile75Leu rs1169288 12 121,416,650 <0.00100 <0.00100 
HNF1A p.Ala146Val HNF1A p.Ala146Val rs1800574 12 121,416,864 0.269 0.867 0.280 0.902 
MPHOSPH9 SBNO1 p.Ser729Asn rs1060105 12 123,806,219 0.00166 0.0539 0.00176 0.0574 
ZZEF1 ZZEF1 p.Ile402Val rs781831 17 3,947,644 <0.00100 0.00129 <0.00100 0.0183 
MLX MLX p.Gln139Arg rs665268 17 40,722,029 0.00210 0.0382 0.00219 0.0398 
TTLL6 
TTLL6 p.Glu712Asp rs2032844 17 46,847,364 <0.00100 <0.00100 
0.0164 0.305 CALCOCO2 p.Pro347Ala rs10278 17 46,939,658 0.0100 0.187 
SNF8 p.Arg155His rs57901004 17 47,011,897 0.00493 0.0917 
C17orf58 C17orf58 p.Ile92Val rs9891146 17 65,988,049 <0.00100 0.00994 <0.00100 0.00995 
CILP2 
TM6SF2 p.Glu167Lys rs58542926 19 19,379,549 0.211 0.732 
0.263 0.913 
TM6SF2 p.Leu156Pro rs187429064 19 19,380,513 0.0495 0.172 
GIPR GIPR p.Glu318Gln rs1800437 19 46,181,392 0.169 0.901 0.169 0.901 
ZHX3 ZHX3 p.Asn310Ser rs17265513 20 39,832,628 <0.00100 0.00287 0.00316 0.110 
HNF4A HNF4A p.Thr139Ile rs1800961 20 43,042,364 1.00 1.00 1.00 1.00 
MTMR3-ASCC2 
ASCC2 p.Asp407His rs28265 22 30,200,761 0.0111 0.192 
0.0278 0.481 
ASCC2 p.Pro423Ser rs36571 22 30,200,713 0.00673 0.116 
ASCC2 p.Val123Ile rs11549795 22 30,221,120 0.00619 0.107 
MTMR3 p.Asn960Ser rs41278853 22 30,416,527 0.00377 0.0652 
PNPLA3 
PNPLA3 p.Ile148Met rs738409 22 44,324,727 0.112 0.691 
0.130 0.806 
PARVB p.Trp37Arg rs1007863 22 44,395,451 0.0167 0.103 
PIM3 
IL17REL p.Leu333Pro rs5771069 22 50,435,480 0.0414 0.419 
0.0470 0.475 IL17REL p.Gly70Arg rs9617090 22 50,439,194 0.00530 0.0536 
PIM3 p.Val300Ala rs4077129 22 50,356,693 <0.00100 0.00176 
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ONLINE METHODS 
 
Ethics statement. All human research was approved by the relevant institutional review 
boards, and conducted according to the Declaration of Helsinki. All participants provided 
written informed consent. 
 
Derivation of significance thresholds. We considered five categories of annotation16 of 
variants on the exome array in order of decreasing effect on biological function: (1) PTVs 
(stop-gain and stop-loss, frameshift indel, donor and acceptor splice-site, and initiator codon 
variants, n1=8,388); (2) moderate-impact variants (missense, in-frame indel, and splice 
region variants, n2=216,114); (3) low-impact variants (synonymous, 3’ and 5’ UTR, and 
upstream and downstream variants, n3=8,829); (4) other variants mapping to DNase I 
hypersensitive sites in any of 217 cell types8 (DHS, n4=3,561); and (5) other variants not 
mapping to DHS (n5=10,578). To account for the greater prior probability of causality for 
variants with greater effect on biological function, we determined a weighted Bonferroni-
corrected significance threshold on the basis of reported enrichment16, denoted wi, in each 
annotation category, i: w1=165; w2=33; w3=3; w4=1.5; w5=0.5. For coding variants 
(annotation categories 1 and 2): 
 
𝛼 =
0.05∑ 𝑛𝑖𝑤𝑖
2
𝑖=1
(∑ 𝑛𝑖
2
𝑖=1 )(∑ 𝑛𝑖𝑤𝑖
5
𝑖=1 )
= 2.21x10−7. 
 
We note that this threshold is similar to a simple Bonferroni correction for the total number 
of coding variants on the array, which would yield: 
 
𝛼 =
0.05
224502
= 2.23x10−7 . 
 
For non-coding variants (annotation categories 3, 4 and 5) the weighted Bonferroni-
corrected significance threshold is: 
 
𝛼 =
0.05∑ 𝑛𝑖𝑤𝑖
5
𝑖=3
(∑ 𝑛𝑖
5
𝑖=3 )(∑ 𝑛𝑖𝑤𝑖
5
𝑖=1 )
= 9.45x10−9. 
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Exome-array study-level analyses. Within each study, genotype calling and quality control 
were undertaken according to protocols developed by the UK Exome Chip Consortium or 
the CHARGE central calling effort39 (Supplementary Table 1). Within each study, variants 
were then excluded for the following reasons: (i) not mapping to autosomes or X 
chromosome; (ii) multi-allelic and/or insertion-deletion; (iii) monomorphic; (iv) call rate 
<99%; or (v) exact p<10-4 for deviation from Hardy-Weinberg equilibrium (autosomes only). 
 We tested association of T2D with each variant in a linear mixed model, 
implemented in RareMetalWorker17, using a genetic relationship matrix (GRM) to account 
for population structure and relatedness. For participants from family-based studies, known 
relationships were incorporated directly in the GRM. For founders and participants from 
population-based studies, the GRM was constructed from pair-wise identity by descent 
(IBD) estimates based on LD pruned (r2<0.05) autosomal variants with MAF≥1%, after 
exclusion of those in high LD and complex regions40,41, and those mapping to established 
T2D loci. We considered additive, dominant, and recessive models for the effect of the 
minor allele, adjusted for age and sex (where appropriate) and additional study-specific 
covariates (Supplementary Table 2). Analyses were also performed with and without 
adjustment for BMI (where available Supplementary Table 2). 
 For single-variant association analyses, variants with minor allele count ≤10 were 
excluded. Association summary statistics for each analysis were corrected for residual 
inflation by means of genomic control42, calculated after excluding variants mapping to 
established T2D susceptibility loci. For gene-based analyses, we made no variant exclusions 
on the basis of minor allele count.   
 
Exome-sequence analyses. We used summary statistics of T2D association analysis 
conducted on 8,321 T2D cases and 8,421 controls from across different ancestries, all 
genotyped using exome sequencing. Details of samples included, sequencing, and quality 
control are described elsewhere12,15 (http://www.type2diabetesgenetics.org/). Samples 
were subdivided into 15 sub-groups according to ancestry and study of origin. Each sub-
group was analysed independently, with sub-group specific principal components and 
genetic relatedness matrices. Association tests were performed with both a linear mixed 
model, as implemented in EMMAX43, using covariates for sequencing batch, and the Firth 
test, using covariates for principal components and sequencing batch. Related samples were 
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excluded from the Firth analysis but maintained in the EMMAX analysis. Variants were then 
filtered from each sub-group analysis, according to call rate, differential case-control 
missing-ness, or deviation from Hardy-Weinberg equilibrium (as computed separately for 
each sub-group). Association statistics were then combined via a fixed-effects inverse-
variance weighted meta-analysis, at both the level of ancestry as well as across all samples. 
P-values were taken from the EMMAX analysis, while effect sizes estimates are taken from 
the Firth analysis. Analyses were performed with and without adjustment for BMI. From 
exome sequence summary statistics, we extracted variants passing quality control and 
present on the exome array. 
 
GWAS analyses. The UK Biobank is a large detailed prospective study of more than 500,000 
participants aged 40-69 years when recruited in 2006-201013. Prevalent T2D status was 
defined using self-reported medical history and medication in UK Biobank participants44. 
Participants were genotyped with the UK Biobank Axiom Array or UK BiLEVE Axiom Array, 
and quality control and population structure analyses were performed centrally at UK 
Biobank. We defined a subset of “white European” ancestry samples (n=120,286) as those 
who both self-identified as white British and were confirmed as ancestrally “Caucasian” 
from the first two axes of genetic variation from principal components analysis. Imputation 
was also performed centrally at UK Biobank for the autosomes only, up to a merged 
reference panel from the 1000 Genomes Project (multi-ethnic, phase 3, October 2014 
release)21 and the UK10K Project9. We used SNPTESTv2.545 to test for association of T2D 
with each SNP in a logistic regression framework under an additive model, and after 
adjustment for age, sex, six axes of genetic variation, and genotyping array as covariates. 
Analyses were performed with and without adjustment for BMI, after removing related 
individuals. 
 GERA is a large multi-ethnic population-based cohort, created for investigating the 
genetic and environmental basis of age-related diseases [dbGaP phs000674.p1]. T2D status 
is based on ICD-9 codes in linked electronic medical health records, with all other 
participants defined as controls. Participants have previously been genotyped using one of 
four custom arrays, which have been designed to maximise coverage of common and low-
frequency variants in non-Hispanic white, East Asian, African American, and Latino 
ethnicities46,47. Methods for quality control have been described previously14. Each of the 
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four genotyping arrays were imputed separately, up to the 1000 Genomes Project reference 
panel (autosomes, phase 3, October 2014 release; X chromosome, phase 1, March 2012 
release) using IMPUTEv2.348,49. We used SNPTESTv2.545 to test for association of T2D with 
each SNP in a logistic regression framework under an additive model, and after adjustment 
for sex and nine axes of genetic variation from principal components analysis as covariates. 
BMI was not available for adjustment in GERA. 
For UK Biobank and GERA, we extracted variants passing standard imputation quality 
control thresholds (IMPUTE info≥0.4)50 and present on the exome array. Association 
summary statistics under an additive model were corrected for residual inflation by means 
of genomic control42, calculated after excluding variants mapping to established T2D 
susceptibility loci: GERA (λ=1.097 for BMI unadjusted analysis) and UK Biobank (λ=1.043 for 
BMI unadjusted analysis, λ=1.056 for BMI adjusted analysis). 
 
Single-variant meta-analysis. We aggregated association summary statistics under an 
additive model across studies, with and without adjustment for BMI, using METAL51: (i) 
effective sample size weighting of Z-scores to obtain p-values; and (ii) inverse variance 
weighting of log-odds ratios. For exome-array studies, allelic effect sizes and standard errors 
obtained from the RareMetalWorker linear mixed model were converted to the log-odds 
scale prior to meta-analysis to correct for case-control imbalance52. 
 The European-specific meta-analyses aggregated association summary statistics 
from a total of 48,286 cases and 250,671 controls from: (i) 33 exome-array studies of 
European ancestry; (ii) exome-array sequence from individuals of European ancestry; and 
(iii) GWAS from UK Biobank. Note that non-coding variants represented on the exome array 
were not available in exome sequence. The European-specific meta-analyses were corrected 
for residual inflation by means of genomic control42, calculated after excluding variants 
mapping to established T2D susceptibility loci: λ=1.091 for BMI unadjusted analysis and 
λ=1.080 for BMI adjusted analysis. 
 The trans-ethnic meta-analyses aggregated association summary statistics from a 
total of 81,412 cases and 370,832 controls across all studies (exome array, exome sequence, 
and GWAS), irrespective of ancestry. Note that non-coding variants represented on the 
exome array were not available in exome sequence. The trans-ethnic meta-analyses were 
corrected for residual inflation by means of genomic control42, calculated after excluding 
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variants mapping to established T2D susceptibility loci: λ=1.073 for BMI unadjusted analysis 
and λ=1.068 for BMI adjusted analysis. Heterogeneity in allelic effect sizes between exome-
array studies contributing to the trans-ethnic meta-analysis was assessed by Cochran’s Q 
statistic53. 
 
Detection of distinct association signals. Conditional analyses were undertaken to detect 
association signals by inclusion of index variants and/or tags for previously reported non-
coding GWAS lead SNPs as covariates in the regression model at the study level. Within each 
exome-array study, approximate conditional analyses were undertaken under a linear mixed 
model using RareMetal17, which uses score statistics and the variance-covariance matrix 
from the RareMetalWorker single-variant analysis to estimate the correlation in effect size 
estimates between variants due to LD. Study-level allelic effect sizes and standard errors 
obtained from the approximate conditional analyses were converted to the log-odds scale 
to correct for case-control imbalance52. Within each GWAS, exact conditional analyses were 
performed under a logistic regression model using SNPTESTv2.545. GWAS variants passing 
standard imputation quality control thresholds (IMPUTE info≥0.4)50 and present on the 
exome array were extracted for meta-analysis. 
 Association summary statistics were aggregated across studies, with and without 
adjustment for BMI, using METAL51: (i) effective sample size weighting of Z-scores to obtain 
p-values; and (ii) inverse variance weighting of log-odds ratios.  
 
Non-additive association models. For exome-array studies only, we aggregated association 
summary statistics under recessive and dominant models across studies, with and without 
adjustment for BMI, using METAL51: (i) effective sample size weighting of Z-scores to obtain 
p-values; and (ii) inverse variance weighting of log-odds ratios. Allelic effect sizes and 
standard errors obtained from the RareMetalWorker linear mixed model were converted to 
the log-odds scale prior to meta-analysis to correct for case-control imbalance52. The 
European-specific meta-analyses aggregated association summary statistics from a total of 
41,066 cases and 136,024 controls from 33 exome-array studies of European ancestry. The 
European-specific meta-analyses were corrected for residual inflation by means of genomic 
control42, calculated after excluding variants mapping to established T2D susceptibility loci: 
λ=1.076 and λ=1.083 for BMI unadjusted analysis, under recessive and dominant models 
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respectively, and λ=1.081 and λ=1.062 for BMI adjusted analysis, under recessive and 
dominant models respectively. The trans-ethnic meta-analyses aggregated association 
summary statistics from a total of 58,425 cases and 188,032 controls across all exome-array 
studies, irrespective of ancestry. The trans-ethnic meta-analyses were corrected for residual 
inflation by means of genomic control42, calculated after excluding variants mapping to 
established T2D susceptibility loci: λ=1.041 and λ=1.071 for BMI unadjusted analysis, under 
recessive and dominant models respectively, and λ=1.031 and λ=1.063 for BMI adjusted 
analysis, under recessive and dominant models respectively. 
 
Gene-based meta-analyses. For exome-array studies only, we aggregated association 
summary statistics under an additive model across studies, with and without adjustment for 
BMI, using RareMetal17. This approach uses score statistics and the variance-covariance 
matrix from the RareMetalWorker single-variant analysis to estimate the correlation in 
effect size estimates between variants due to LD. We performed gene-based analyses using 
a burden test (assuming all variants have same direction of effect on T2D susceptibility) and 
SKAT (allowing variants to have different directions of effect on T2D susceptibility). We used 
two previously defined filters for annotation and MAF18 to define group files: (i) strict filter, 
including 44,666 variants; and (ii) broad filter, including all variants from the strict filter, and 
97,187 additional variants. 
 We assessed the contribution of each variant to gene-based signals by performing 
approximate conditional analyses. We repeated RareMetal analyses for the gene, excluding 
each variant in turn from the group file, and compared the strength of the association 
signal. 
 
Fine-mapping of coding variant association signals with T2D susceptibility. We defined a 
locus as mapping 500kb up- and down-stream of each index coding variant (Supplementary 
Table 5), excluding the MHC. Our fine-mapping analyses aggregated association summary 
statistics from 24 GWAS incorporating 41,284 T2D cases and 311,715 controls of European 
ancestry from the DIAGRAM Consortium (Supplementary Table 8). Each GWAS was imputed 
using miniMAC12 or IMPUTEv248,49 up to reference panels from the Haplotype Reference 
Consortium20, the 1000 Genomes Project (multi-ethnic, phase 3, October 2014 release)21 
and the UK10K Project9, or population-specific whole-genome sequence data19 
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(Supplementary Table 8). Association with T2D susceptibility was tested for each remaining 
variant using logistic regression, adjusting for age, sex, and study-specific covariates, under 
an additive genetic model. Analyses were performed with and without adjustment for BMI. 
For each study, variants with minor allele count<5 or those with imputation quality r2-
hat<0.3 (miniMAC) or proper-info<0.4 (IMPUTE2) were removed. Association summary 
statistics for each analysis were corrected for residual inflation by means of genomic 
control42, calculated after excluding variants mapping to established T2D susceptibility loci. 
We aggregated association summary statistics across studies, with and without 
adjustment for BMI, in a fixed-effects inverse variance weighted meta-analysis, using 
METAL51. The BMI unadjusted meta-analysis was corrected for residual inflation by means of 
genomic control (λ=1.012)42, calculated after excluding variants mapping to established T2D 
susceptibility loci. No adjustment was required for BMI adjusted meta-analysis (λ=0.994). 
From the meta-analysis, variants were extracted that were present on the HRC panel and 
reported in at least 50% of total effective sample size.  
To delineate distinct association signals in four regions, we undertook approximate 
conditional analyses, implemented in GCTA54, to adjust for the index coding variants and 
non-coding lead GWAS SNPs: (i) RREB1 p. Asp1171Asn, p.Ser1499Tyr, and rs9505118; (ii) 
HNF1A p.Ile75Leu and p.Ala146Val; (iii) GIPR p.Glu318Gln and rs8108269; and (iv) HNF4A 
p.Thr139Ile and rs4812831. We made use of summary statistics from the fixed-effects meta-
analyses (BMI unadjusted for RREB1, HNF1A, and HNF4A, and BMI adjusted for GIPR as this 
signal was only seen in BMI adjusted analysis) and genotype data from 5,000 random 
individuals of European ancestry from the UK Biobank, as reference for LD between genetic 
variants across the region. 
 For each association signal, we first calculated an approximate Bayes’ factor55 in 
favour of association on the basis of allelic effect sizes and standard errors from the meta-
analysis. Specifically, for the jth variant, 
 
𝛬𝑗 = √
𝑉𝑗
𝑉𝑗+𝜔
exp [
𝜔𝛽𝑗
2
2𝑉𝑗(𝑉𝑗+𝜔)
], 
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where βj and Vj denote the estimated allelic effect (log-OR) and corresponding variance 
from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken 
here to be 0.0455.   
We then calculated the posterior probability that the jth variant drives the 
association signal, given by 
 
𝜋𝑗 =
𝜌𝑗𝛬𝑗
∑ 𝜌𝑘𝛬𝑘𝑘
. 
 
In this expression, ρj denotes the prior probability that the jth variant drives the association 
signal, and the summation in the denominator is over all variants across the locus. We 
considered two prior models: (i) functionally unweighted, for which ρj = 1 for all variants; 
and (ii) annotation informed, for which ρj is determined by the functional severity of the 
variant. For the annotation informed prior, we considered five categories of variation16, such 
that: (i) ρj = 165 for PTVs; (ii) ρj = 33 for moderate-impact variants; (iii) ρj = 3 for low-impact 
variants; (iv) ρj = 1.5 for other variants mapping to DHS; and (v) ρj = 0.5 for all other variants. 
 For each locus, the 99% credible set22 under each prior was then constructed by: (i) 
ranking all variants according to their posterior probability of driving the association signal; 
and (ii) including ranked variants until their cumulative posterior probability of driving the 
association attained or exceeded 0.99. 
 
Functional impact of coding alleles. We used CADD35 to obtain scaled Combined Annotation 
Dependent Depletion score (CADD-scores) for each of the 40 significantly associated coding 
variants. The CADD method objectively integrates a range of different annotation metrics 
into a single measure (CADD-score), providing an estimate of deleteriousness for all known 
variants and an overall rank for this metric across the genome. We obtained the estimates 
of the intolerance of a gene to harbouring loss-of-function variants (pLI) from the ExAC data 
set34. We used the Kolmogorov-Smirnov test to determine whether fine-mapping groups 1 
and 2 have the same statistical distribution for each of these parameters.  
 
T2D loci and physiological classification. To explore the different patterns of association 
between T2D and other anthropometric/metabolic/endocrine traits and diseases, we 
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performed hierarchical clustering analysis. We obtained association summary statistics for a 
range of metabolic traits and other outcomes for 94 coding and non-coding variants that 
were significantly associated with T2D through collaboration or by querying publically 
available GWAS meta-analysis datasets. The z-score (allelic effect/SE) was aligned to the 
T2D-risk allele. We obtained the distance matrix amongst z-score of the loci/traits using the 
Euclidean measure and performed clustering using the complete agglomeration method. 
Clustering was visualised it by constructing dendogram and a heatmap.  
Data availability.  
39. Grove, M.L. et al. Best practices and joint calling of the HumanExome BeadChip: the 
CHARGE Consortium. PLoS One 8, e68095 (2013). 
40. Price, A.L. et al. Long-range LD can confound genome scans in admixed populations. 
Am J Hum Genet 83, 132-5; author reply 135-9 (2008). 
41. Weale, M.E. Quality control for genome-wide association studies. Methods Mol Biol 
628, 341-72 (2010). 
42. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997-
1004 (1999). 
43. Kang, H.M. et al. Variance component model to account for sample structure in 
genome-wide association studies. Nat Genet 42, 348-54 (2010). 
44. Eastwood, S.V. et al. Algorithms for the Capture and Adjudication of Prevalent and 
Incident Diabetes in UK Biobank. PLoS One 11, e0162388 (2016). 
45. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. 
Nat Rev Genet 11, 499-511 (2010). 
46. Hoffmann, T.J. et al. Next generation genome-wide association tool: design and 
coverage of a high-throughput European-optimized SNP array. Genomics 98, 79-89 
(2011). 
47. Hoffmann, T.J. et al. Design and coverage of high throughput genotyping arrays 
optimized for individuals of East Asian, African American, and Latino race/ethnicity 
using imputation and a novel hybrid SNP selection algorithm. Genomics 98, 422-30 
(2011). 
46 
 
48. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation 
method for the next generation of genome-wide association studies. PLoS Genet 5, 
e1000529 (2009). 
49. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and 
accurate genotype imputation in genome-wide association studies through pre-
phasing. Nat Genet 44, 955-9 (2012). 
50. Winkler, T.W. et al. Quality control and conduct of genome-wide association meta-
analyses. Nat Protoc 9, 1192-212 (2014). 
51. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics 26, 2190-1 (2010). 
52. Cook, J.P., Mahajan, A. & Morris, A.P. Guidance for the utility of linear models in 
meta-analysis of genetic association studies of binary phenotypes. Eur J Hum Genet 
25, 240-245 (2017). 
53. Ioannidis, J.P., Patsopoulos, N.A. & Evangelou, E. Heterogeneity in meta-analyses of 
genome-wide association investigations. PLoS One 2, e841 (2007). 
54. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics 
identifies additional variants influencing complex traits. Nat Genet 44, 369-75, s1-3 
(2012). 
55. Wakefield, J. A Bayesian measure of the probability of false discovery in genetic 
epidemiology studies. Am J Hum Genet 81, 208-27 (2007). 
 
URLs 
Type 2 Diabetes Knowledge Portal: http://www.type2diabetesgenetics.org/ 
 
 
 
